Early use of high|efficacy disease‑modifying therapies makes the ...

Early use of high-efficacy disease‑modifying therapies ... - PubMed

Early intervention with high-efficacy disease-modifying therapies (HE-DMTs) may represent the best window of opportunity to delay irreversible ...

Early use of high-efficacy disease‑modifying therapies makes the ...

Early use of high-efficacy disease‐modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

Early use of high-efficacy therapies in multiple sclerosis in the ...

An important note is that this classification based on ARR does not account for DMT effects on MRI, disability, or other disease measures, and ...

(PDF) Early use of high-efficacy disease‑modifying therapies makes ...

Early intervention with high-efficacy disease-modifying therapies (HE-DMTs) may represent the best window of opportunity to delay irreversible ...

Initial high-efficacy disease-modifying therapy in multiple sclerosis

This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.

Early Initiation of High Efficacy Disease Modifying Therapies in ...

Ocrelizumab, cladribine and alemtuzumab reduce relapses and MRI activity and prevent disease progression when are initiated early in naive RRMS patients.

Correction to: Early use of high-efficacy disease-modifying therapies ...

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.

Early High Efficacy Treatment in Multiple Sclerosis Is the Best ...

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on disease activity. The current treatment ...

An argument for broad use of high efficacy treatments in early ...

found a median delay of 2.4 years in patients who escalated disease-modifying agents. Another issue is a period of vulnerability that may exist ...

timing of high-efficacy disease modifying therapies for relapsing ...

The patients treated early with high-efficacy DMTs experienced less relapses (annualised relapse rate 0.22 versus 0.42) and were more likely to recover from ...

Long-term clinical outcomes in patients with multiple sclerosis who ...

The difference in relapse outcomes observed for these matched populations highlights benefit of high-efficacy DMT options as first-line therapy ...

Disease Modification & DMT's for MS - National MS Society

There is a large body of evidence that supports early and ongoing treatment with an approved disease-modifying therapy (DMT) as an evidence-based approach.

Evolution of Disease Modifying Therapy Benefits and Risks - Frontiers

Background: Strategies for sequencing disease modifying therapies (DMTs) in multiple sclerosis (MS) patients include escalation, high efficacy early, induction, ...

Initiation Patterns of Disease-Modifying Therapies for Multiple ...

Other factors, including insurance formulary restrictions, may have also limited the use of high-efficacy DMTs (eg, natalizumab and ocrelizumab) ...

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis

The literature suggests that treatment with high-efficacy immunotherapies is more potent in suppressing relapse activity when initiated early vs. with a delay ...

Escalating to medium‐ versus high‐efficacy disease modifying ...

These results imply that patients initially treated with an escalation approach (i.e., first treatment with a low-efficacy DMT) could benefit ...

Personalized Use of Disease-Modifying Therapies in Multiple ...

Fingolimod is considered a DMT of moderate-to-high efficacy. It is approved in the US as a first-line DMT for relapsing MS and as a second-line DMT in Europe.

Early use of high-efficacy disease‑modifying therapies makes the ...

Early intervention with high-efficacy disease-modifying therapies (HE-DMTs) may represent the best window of opportunity to delay irreversible central ...

Sequencing of high-efficacy disease-modifying therapies in multiple ...

Currently available disease-modifying therapies (DMTs) for relapsing MS have been demonstrated to reduce disease activity, however most patients require a ...

Correction to: Early use of high-efficacy disease-modifying therapies ...

The article Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion, written by ...